NASDAQ:QNCX Quince Therapeutics Q4 2024 Earnings Report $1.43 +0.23 (+19.17%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.37 -0.06 (-4.13%) As of 06/13/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Quince Therapeutics EPS ResultsActual EPS-$0.28Consensus EPS -$0.19Beat/MissMissed by -$0.09One Year Ago EPSN/AQuince Therapeutics Revenue ResultsActual Revenue$0.17 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQuince Therapeutics Announcement DetailsQuarterQ4 2024Date3/24/2025TimeAfter Market ClosesConference Call DateMonday, March 24, 2025Conference Call Time4:00PM ETUpcoming EarningsQuince Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Quince Therapeutics Earnings HeadlinesQuince Therapeutics Raises $11.5M in Private PlacementJune 13 at 6:14 PM | tipranks.comQuince Therapeutics Announces Pricing of Up to $22 Million Private Placement of SecuritiesJune 12 at 5:15 PM | businesswire.comBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…June 14, 2025 | Crypto 101 Media (Ad)Quince Therapeutics' (QNCX) Buy Rating Reiterated at D. Boral CapitalJune 6, 2025 | americanbankingnews.comAnalysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $8.00June 4, 2025 | americanbankingnews.comQuince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJune 3, 2025 | businesswire.comSee More Quince Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quince Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quince Therapeutics and other key companies, straight to your email. Email Address About Quince TherapeuticsQuince Therapeutics (NASDAQ:QNCX), a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.View Quince Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Wells Fargo & Company (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
